Process in the treatment of non-infectious uveitis with Adalimumab

Guoji Yanke Zazhi

Yan-Ting Pan¹  Li-Ping Xue¹  Chuan-Hong Zhang¹  Shu-Xian Hu²  Yu-Ting Li² 

[1] The Fourth Affiliated Hospital of Kunming Medical University;The Second People's Hospital of Yunnan Province, Kunming 650021, Yunnan Province, China;

关键词: adalimumab;    non-infectious uveitis;    tnf-α inhibitors;    drug therapy;    progress;   

DOI  :  10.3980/j.issn.1672-5123.2021.9.14

来源: DOAJ

【 摘 要 】

Uveitis is a clinically common refractory blinding eye disease with complicated etiology and pathogenesis that is difficult to treat and prone to recurrence. It is currently considered to be closely associated autoimmune inflammatory response. Tumor necrosis factor-α(TNF-α)acts as a key pro-inflammatory factor in development and progression of uveitis. Adalimumab(ADA)is a fully humanized recombinant anti-immunoglobulin monoclonal antibody targeting TNF-α, and exerts its biological effects by specifically binding to TNF-α and blocking its binding to tumor necrosis factor receptors(TNFR-1/TNFR-2). This paper reviews the clinical research progress on the mechanism, efficacy and safety of ADA in the treatment of non-infectious uveitis.

【 授权许可】

Unknown